Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Dexcom (DC4) Stock Price & Analysis

0 Followers

DC4 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 24.60B
Enterprise Value
CHF 32.67B
Total Cash (Recent Filing)
CHF 1.82B
Total Debt (Recent Filing)
CHF 1.39B
Price to Earnings (P/E)
30.9
Beta
N/A
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
0.58
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring CGM Revenue

Dexcom’s sensor replacement cycle creates recurring revenue and supports customer retention after initial adoption. This model provides a durable base for forecasting, while ongoing reimbursement, channel access, and connected-care partnerships can expand utilization and deepen the value of each customer relationship.

Revenue And Margin Expansion

Strong revenue growth alongside high gross and net margins indicates meaningful operating scale and a profitable business model. Continued margin expansion would increase internal funding for product development, international expansion, and digital initiatives while strengthening Dexcom’s ability to compete over the next several quarters.

Market Share And Clinical Strength

Share gains across customer segments, supported by strong clinical evidence, reinforce Dexcom’s product credibility with patients, clinicians, and reimbursement bodies. This combination can support durable adoption, broaden use among type 2 customers, and strengthen the company’s competitive position in CGM.

Bears Say

Weaker Cash Conversion

Recent deterioration in cash conversion means reported earnings are translating into less incremental cash than before. Although absolute cash generation remains substantial, higher investment or working-capital needs could reduce funding available for expansion, buybacks, and other capital-allocation priorities.

Slower International Growth

Slower international growth creates a drag on consolidated expansion and shows that reimbursement-driven gains may not repeat evenly across markets. A prolonged normalization period could delay the benefits of global scale, limit geographic diversification, and require continued investment to rebuild adoption momentum.

Preferred PBM Access Loss

Loss of preferred access can raise patient costs and make Dexcom’s products less attractive for affected members, creating friction in new starts and retention. Even with a limited direct revenue exposure, the issue increases reliance on alternative pathways such as medical benefits and Dexcom Direct.

Dexcom News

DC4 FAQ

What is Dexcom’s market cap?
Dexcom’s market cap is CHF24.60B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 92 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 29, 2026. The company reported CHF0.596 earnings per share for the quarter, beating the consensus estimate of CHF0.551 by CHF0.045.
Is Dexcom overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.58.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of CHF0.596 in its last earnings report, beating expectations of CHF0.551. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Dexcom?
Hedge funds hold Dexcom shares: the largest hedge-fund position in Dexcom is 1,687,594,280 shares, and hedge funds increased their holdings by 306.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology